EDITHealthcare · BiotechnologyThe 13 Wall Street analysts covering Editas Medicine, Inc. hold a median 12-month price target of $5 — +66.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Editas Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (97): Sales and profits are climbing, and climbing faster than before.
Volatility (19): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EDIT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +66.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Ladenburg Thalmann | Initiates | Buy | $6.00 |
| 5 May 2026 | Chardan Capital | Maintains | Buy | — |
| 5 May 2026 | Chardan Capital | Maintains | Buy | $3.50 → $4.00 |
| 10 Mar 2026 | Jones Trading | Upgrade | Buy | — |
| 9 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 5 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2025 | Baird | Maintains | Outperform | — |
| 13 May 2025 | Baird | Maintains | Outperform | — |
| 28 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Dec 2024 | Evercore ISI Group | Maintains | Outperform | — |
| 16 Dec 2024 | JP Morgan | Downgrade | Underweight | — |
| 13 Dec 2024 | Baird | Maintains | Outperform | — |
| 13 Dec 2024 | Barclays | Maintains | Equal-Weight | — |
| 13 Dec 2024 | Chardan Capital | Downgrade | Neutral | — |
| 13 Dec 2024 | RBC Capital | Maintains | Sector Perform | — |
| 13 Dec 2024 | Stifel | Downgrade | Hold | — |
| 11 Dec 2024 | Wells Fargo | Downgrade | Equal-Weight | — |
| 5 Nov 2024 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EDIT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Editas Medicine, Inc. returned +7.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 15% of US stocks
Cheaper than 24% of US stocks
Cheaper than 75% of US stocks
Higher than 96% of US stocks
Higher than 91% of US stocks
Higher than 11% of US stocks
Higher than 3% of US stocks
Higher than 11% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Editas Medicine, Inc. has a market value of $477.6M and an enterprise value of $281.5M.
Revenue in the twelve months to 30 June 2026: $47.0M. The latest quarter grew 232.3% year on year.
Net income over the same four quarters: −$73.9M, a −157.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.75.
Free cash flow in the twelve months to 30 June 2026: −$120.5M.
Trailing P/E: −1.7×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Editas Medicine, Inc. employs 87 people — $540K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Editas Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research article compares the year-to-date performance of Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) against their sector.
Why it matters — EDIT watchers can see how the stock has performed relative to its sector and a peer so far this year.
Editas Medicine reported Q2 results that beat estimates, with revenues rising on a surge in collaboration revenue. The company also advanced EDIT-401 toward clinical testing, citing encouraging preclinical data.
Why it matters — A watcher of Editas would care because the earnings beat, higher collaboration revenue, and progress of EDIT-401 toward clinical testing point to momentum in both the company's financial and pipeline development.
Editas Medicine reported Q2 2026 financial results, noting progress with EDIT-401 toward a CTN submission in August 2026 and a data update expected in Q1 2027. The company also highlighted a recent financing that extends its cash runway into the second half of 2028.
Why it matters — An EDIT watcher would care because the EDIT-401 program is advancing toward regulatory submission and the extended cash runway reduces near-term financing risk.
Editas Medicine announced the appointment of Patrick T. Ellinor, M.D., a recognized leader in cardiovascular medicine and human genetics, to its board of directors. His experience spans scientific innovation, therapeutic discovery, and clinical leadership as the company advances EDIT-401 toward the clinic.
Why it matters — A director with cardiovascular and genetics expertise could be relevant to Editas shareholders as the company progresses its cardiovascular gene-editing program, EDIT-401.
The 13 Wall Street analysts covering Editas Medicine, Inc. have a median 12-month price target of $5, with estimates ranging from $1 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Editas Medicine, Inc., 7 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Editas Medicine, Inc. 76 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Editas Medicine, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +66.1% from the last close, and Ticker Nerd's factor model ranks Editas Medicine, Inc. 76 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Editas Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDIT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $15 over the next 12 months.
Editas Medicine, Inc. returned +7.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Editas Medicine Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases.
The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?". A Zacks Investment Research article compares the year-to-date performance of Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) against their sector.
Editas Medicine Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company uses CRISPR-based platforms, including CRISPR/Cas9 and CRISPR/Cas12a, to research and develop precision therapies designed to address underlying genetic causes of illness. Its current work centers on in vivo and ex vivo gene editing programs across areas such as ocular disorders, blood diseases, oncology, and other severe conditions. Editas Medicine Inc. operates as a gene editing specialist within the healthcare market, where its role is to translate advanced genome engineering tools into potential therapeutic products for patients with significant unmet medical needs. Headquartered in Cambridge, Massachusetts, the company is recognized for its focus on transformative genomic medicines and its pipeline of investigational candidates.
CEO Dr. Gilmore O'Neill M.D. · 87 employees · United States · https://www.editasmedicine.com
